{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:53:34Z","timestamp":1793732014298,"version":"4.6.1"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Royal College of Surgeons of England Research Fellowship and a British Association of Surgical Oncologists Research Project Grant","id":[{"id":"https:\/\/ror.org\/023z8b445","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Cancer Research UK and Royal College of Surgeons of England Advanced Clinician Scientist Fellowship","award":["A23924"],"award-info":[{"award-number":["A23924"]}],"id":[{"id":"https:\/\/ror.org\/02qrg5a24","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Upper Gastrointestinal Surgery, Heartburn Cancer UK, and the Royal College of Surgeons of England Surgical Specialty Lead Programme","id":[{"id":"https:\/\/ror.org\/02qrg5a24","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Perioperative chemotherapy is widely used in the treatment of oesophagogastric adenocarcinoma (OGAC) with a substantial survival benefit over surgery alone. However, the postoperative part of these regimens is given in less than half of patients, reflecting uncertainty among clinicians about its benefit and poor postoperative patient fitness. This study estimated the effect of postoperative chemotherapy after surgery for OGAC using a large population-based data set.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with adenocarcinoma of the oesophagus, gastro-oesophageal junction or stomach diagnosed between 2012 and 2018, who underwent preoperative chemotherapy followed by surgery, were identified from a national-level audit in England and Wales. Postoperative therapy was defined as the receipt of systemic chemotherapy within 90 days of surgery. The effectiveness of postoperative chemotherapy compared with observation was estimated using inverse propensity treatment weighting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Postoperative chemotherapy was given to 1593 of 4139 patients (38.5 per cent) included in the study. Almost all patients received platinum-based triplet regimens (4004 patients, 96.7 per cent), with FLOT used in 3.3 per cent. Patients who received postoperative chemotherapy were younger, with a lower ASA grade, and were less likely to have surgical complications, with similar tumour characteristics. After weighting, the median survival time after postoperative chemotherapy was 62.7 months compared with 50.4 months without chemotherapy (hazard ratio 0.84, 95 per cent c.i. 0.77 to 0.94; P = 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study has shown that postoperative chemotherapy improves overall survival in patients with OGAC treated with preoperative chemotherapy and surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjs\/znab427","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T15:18:04Z","timestamp":1637162284000},"page":"227-236","source":"Crossref","is-referenced-by-count":33,"title":["Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery"],"prefix":"10.1093","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9489-0021","authenticated-orcid":false,"given":"Saqib","family":"Rahman","sequence":"first","affiliation":[{"name":"School of Cancer Sciences, Faculty of Medicine, University of Southampton , Southampton, UK"},{"name":"Clinical Effectiveness Unit, Royal College of Surgeons of England , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsan","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Oncology, Velindre University NHS Trust , Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Maynard","sequence":"additional","affiliation":[{"name":"Department of Upper Gastrointestinal Surgery, Oxford University Hospitals NHS Trust , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Hae","family":"Park","sequence":"additional","affiliation":[{"name":"Clinical Effectiveness Unit, Royal College of Surgeons of England , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Wahedally","sequence":"additional","affiliation":[{"name":"Clinical Effectiveness Unit, Royal College of Surgeons of England , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Trudgill","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sandwell and West Birmingham Hospitals NHS Trust , Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Crosby","sequence":"additional","affiliation":[{"name":"Department of Oncology, Velindre University NHS Trust , Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Cromwell","sequence":"additional","affiliation":[{"name":"Clinical Effectiveness Unit, Royal College of Surgeons of England , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim J.","family":"Underwood","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, Faculty of Medicine, University of Southampton , Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"2023063011054794900_znab427-B1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"2023063011054794900_znab427-B2","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","article-title":"Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer","volume":"27","author":"Allum","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023063011054794900_znab427-B3","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"2023063011054794900_znab427-B4","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"2023063011054794900_znab427-B5","volume-title":"National Oesophago-Gastric Cancer Audit: 2019 Annual Report","author":"Cromwell","year":"2019."},{"key":"2023063011054794900_znab427-B6","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/bjs.10627","article-title":"Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma","volume":"104","author":"Noble","year":"2017","journal-title":"Br J Surg"},{"key":"2023063011054794900_znab427-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-014-0356-0","article-title":"Adjuvant or neoadjuvant therapy for operable esophagogastric cancer?","volume":"18","author":"Moorcraft","year":"2015","journal-title":"Gastric Cancer"},{"key":"2023063011054794900_znab427-B8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1200\/JCO.2011.38.9791","article-title":"Health-related quality of life among 5-year survivors of esophageal cancer surgery: a prospective population-based study","volume":"30","author":"Derogar","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023063011054794900_znab427-B9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jamasurg.2018.3752","article-title":"Long-term oncological and functional outcomes of chemoradiotherapy followed by organ-sparing transanal endoscopic microsurgery for distal rectal cancer","volume":"154","author":"Stijns","year":"2019","journal-title":"JAMA Surg"},{"key":"2023063011054794900_znab427-B10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/SLA.0000000000001954","article-title":"Utility of adjuvant chemotherapy after neoadjuvant chemoradiation and esophagectomy for esophageal cancer","volume":"266","author":"Burt","year":"2017","journal-title":"Ann Surg"},{"key":"2023063011054794900_znab427-B11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaoncol.2017.2805","article-title":"Adjuvant chemotherapy vs postoperative observation following preoperative chemoradiotherapy and resection in gastroesophageal cancer a propensity score-matched analysis","volume":"4","author":"Mokdad","year":"2018","journal-title":"JAMA Oncol"},{"key":"2023063011054794900_znab427-B12","doi-asserted-by":"crossref","first-page":"e000386","DOI":"10.1136\/esmoopen-2018-000386","article-title":"Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy","volume":"3","author":"Nevala-Plagemann","year":"2018","journal-title":"ESMO Open"},{"key":"2023063011054794900_znab427-B13","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1245\/s10434-020-09045-w","article-title":"Analysis of the survival impact of postoperative chemotherapy after preoperative chemotherapy and resection for gastric cancer","volume":"28","author":"Drake","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"2023063011054794900_znab427-B14","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.ejso.2015.07.010","article-title":"Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: postoperative chemotherapy has a substantial impact on outcome","volume":"41","author":"Glatz","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"2023063011054794900_znab427-B15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.suronc.2017.06.001","article-title":"The postoperative part of perioperative chemotherapy fails to provide a survival benefit in completely resected esophagogastric adenocarcinoma","volume":"33","author":"Sisic","year":"2020","journal-title":"Surg Oncol"},{"key":"2023063011054794900_znab427-B16","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s11605-018-04087-8","article-title":"The role of continuing perioperative chemotherapy post surgery in patients with esophageal or gastroesophageal junction adenocarcinoma: a multicenter cohort study","volume":"23","author":"Papaxoinis","year":"2019","journal-title":"J Gastrointest Surg"},{"key":"2023063011054794900_znab427-B17","doi-asserted-by":"crossref","first-page":"15L","DOI":"10.1093\/ije\/dyz137","article-title":"Data resource profile: The Systemic Anti-Cancer Therapy (SACT) data set","volume":"49","author":"Bright","year":"2020","journal-title":"Int J Epidemiol"},{"key":"2023063011054794900_znab427-B18","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"2023063011054794900_znab427-B19","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2023063011054794900_znab427-B20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejca.2017.04.027","article-title":"Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial","volume":"81","author":"Stahl","year":"2017","journal-title":"Eur J Cancer"},{"key":"2023063011054794900_znab427-B21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10120-018-0901-3","article-title":"Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis","volume":"22","author":"Petrelli","year":"2019","journal-title":"Gastric Cancer"},{"key":"2023063011054794900_znab427-B22","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.ejso.2020.06.038","article-title":"Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: inverse propensity score weighted analysis","volume":"46","author":"Pucher","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"2023063011054794900_znab427-B23","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmacoepidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2023063011054794900_znab427-B24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","article-title":"Landmark analysis at the 25-year landmark point","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2023063011054794900_znab427-B25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"2023063011054794900_znab427-B26","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2023063011054794900_znab427-B27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1471-2288-12-70","article-title":"Evaluation of the propensity score methods for estimating marginal odds ratios in case of small sample size","volume":"12","author":"Pirracchio","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"2023063011054794900_znab427-B28","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1002\/sim.7084","article-title":"Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis","volume":"35","author":"Austin","year":"2016","journal-title":"Stat Med"},{"key":"2023063011054794900_znab427-B29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0962280217713032","article-title":"Propensity score analysis with partially observed covariates: how should multiple imputation be used?","volume":"28","author":"Leyrat","year":"2019","journal-title":"Stat Methods Med Res"},{"key":"2023063011054794900_znab427-B30","author":"Grabsch","year":"2019."},{"key":"2023063011054794900_znab427-B31","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/sim.2580","article-title":"A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study","volume":"26","author":"Austin","year":"2007","journal-title":"Stat Med"},{"key":"2023063011054794900_znab427-B32","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/sim.2053","article-title":"The use of the propensity score for estimating treatment effects: administrative versus clinical data","volume":"24","author":"Austin","year":"2005","journal-title":"Stat Med"},{"key":"2023063011054794900_znab427-B33","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2023063011054794900_znab427-B34","first-page":"1","article-title":"MICE: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"2023063011054794900_znab427-B35","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"2023063011054794900_znab427-B36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards regression model","volume":"69","author":"Schoenfeld","year":"1982","journal-title":"Biometrika"},{"key":"2023063011054794900_znab427-B37","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.4274","article-title":"The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt","volume":"30","author":"Royston","year":"2011","journal-title":"Stat Med"},{"key":"2023063011054794900_znab427-B38","first-page":"1","article-title":"Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards","volume":"357","author":"Dehbi","year":"2017","journal-title":"BMJ"},{"key":"2023063011054794900_znab427-B39","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2015.64.2488","article-title":"Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials","volume":"34","author":"Trinquart","year":"2016","journal-title":"J Clin Oncol"},{"key":"2023063011054794900_znab427-B40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/biom.12384","article-title":"On the restricted mean survival time curve in survival analysis","volume":"72","author":"Zhao","year":"2016","journal-title":"Biometrics"},{"key":"2023063011054794900_znab427-B41","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1200\/JCO.2016.67.8045","article-title":"Restricted mean survival time: an obligatory end point for time-to-event analysis in cancer trials?","volume":"34","author":"A\u2019Hern","year":"2016","journal-title":"J Clin Oncol"},{"key":"2023063011054794900_znab427-B42","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.clon.2018.04.011","article-title":"Cancer biology and survival analysis in cancer trials: restricted mean survival time analysis versus hazard ratios","volume":"30","author":"A\u2019Hern","year":"2018","journal-title":"Clin Oncol"},{"key":"2023063011054794900_znab427-B43","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"Van Der Weele","year":"2017","journal-title":"Ann Intern Med"},{"key":"2023063011054794900_znab427-B44","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2019."},{"key":"2023063011054794900_znab427-B45","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"2023063011054794900_znab427-B46","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S1470-2045(17)30447-3","article-title":"Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial","volume":"18","author":"Alderson","year":"2017","journal-title":"Lancet Oncol"},{"key":"2023063011054794900_znab427-B47","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1470-2045(17)30043-8","article-title":"Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2\u20133 trial","volume":"18","author":"Cunningham","year":"2017","journal-title":"Lancet Oncol"},{"key":"2023063011054794900_znab427-B48","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/bjs.11461","article-title":"Machine learning to predict early recurrence after oesophageal cancer surgery","volume":"107","author":"Rahman","year":"2020","journal-title":"Br J Surg"},{"key":"2023063011054794900_znab427-B49","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/bjs.10900","article-title":"Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma","volume":"105","author":"Davies","year":"2018","journal-title":"Br J Surg"},{"key":"2023063011054794900_znab427-B50","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004794","article-title":"The AUGIS survival predictor","author":"Rahman","year":"2021","journal-title":"Ann Surg"},{"key":"2023063011054794900_znab427-B51","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/jso.23484","article-title":"The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction","volume":"109","author":"Curtis","year":"2014","journal-title":"J Surg Oncol"},{"key":"2023063011054794900_znab427-B52","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/SLA.0000000000003210","article-title":"Reporting national outcomes after esophagectomy and gastrectomy according to the Esophageal Complications Consensus Group (ECCG)","volume":"271","author":"van der Werf","year":"2020","journal-title":"Ann Surg"},{"key":"2023063011054794900_znab427-B53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/SLA.0000000000002611","article-title":"Benchmarking complications associated with esophagectomy","volume":"269","author":"Low","year":"2019","journal-title":"Ann Surg"},{"key":"2023063011054794900_znab427-B54","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/bjs5.64","article-title":"Meta-analysis of the impact of postoperative complications on survival after oesophagectomy for cancer","volume":"2","author":"Booka","year":"2018","journal-title":"BJS Open"},{"key":"2023063011054794900_znab427-B55","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/bjs.10640","article-title":"Influence of national centralization of oesophagogastric cancer on management and clinical outcome from emergency upper gastrointestinal conditions","volume":"105","author":"Markar","year":"2018","journal-title":"Br J Surg"},{"key":"2023063011054794900_znab427-B56","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJMoa1805101","article-title":"Hybrid minimally invasive esophagectomy for esophageal cancer","volume":"380","author":"Mariette","year":"2019","journal-title":"N Engl J Med"},{"key":"2023063011054794900_znab427-B57","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"key":"2023063011054794900_znab427-B58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2017.74.9846","article-title":"Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma","volume":"36","author":"Doi","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023063011054794900_znab427-B59","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/MOG.0000000000000542","article-title":"The emerging role of immunotherapy for esophageal cancer","volume":"35","author":"Kelly","year":"2019","journal-title":"Curr Opin Gastroenterol"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/109\/2\/227\/50747827\/znab427.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/109\/2\/227\/50747827\/znab427.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T07:06:41Z","timestamp":1688108801000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/109\/2\/227\/6463047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,12,15]]},"published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bjs\/znab427","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,12,15]]}}}